Cineplex: Consensus Price Target Sees Marginal Lift Post Earnings

Cineplex Inc. (TSX: CGX) reported their first-quarter financial results last week, with the company reporting $41 million in revenue, down 85% year over year. Gross margin came in at 69.6%, 390bps higher than it was a year ago, net income meanwhile was $(90) and earnings per share was $(1.42)

A few analysts changed their 12-month price target on Cineplex after the earnings, with the companies 12-month price target slowly inching up to $13.00 from the $12.64 average last month via a total of seven analysts. National Bank has the highest 12-month price target of $17 while the lowest is a $9 price target.

In BMO’s note, their analyst Tim Casey reiterated his market perform rating and $12 price target on the company. Casey refers to this quarter as “not meaningful,” as the business was still locked down and they are looking forward to the second half of 2021 when they are forecasting things to get better.

Casey writes, “We expect marginal improvements in operating results for Q2 and then a step up in H2/21, assuming a relatively stable economic re-opening and consumer recovery,” but remains cautious on the idea that we will get full back to normal as headwinds continue to persist. Casey adds, “We continue to be encouraged by the recovery in the U.S., but we believe the new sustainable level will be at one below pre-COVID levels.”

Below you can see BMO’s updated forecasts for 2021 and 2022.


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Agnico Q1 Earnings Results Overshadowed By A Sinking Gold Price

Why More People Are Starting to Feel Broke | Darrell Thomas – VRIC Media

Newmont Q1 Earnings: A Billion In Free Cash Flow… A Month!

Recommended

Selkirk Copper Strikes New Lens Beneath Old Pit, Launches 50,000 Metre Phase 2 Program

Silver47 Pulls High-Grade Gold and Silver Assays from Nevada Vein Network At Kennedy

Related News

Medmen: Canaccord Raises Price Target, Rating After Q4 Performance

On September 23, Medmen Enterprises (CSE: MMEN) reported their fiscal fourth-quarter financial results. The company...

Saturday, September 25, 2021, 01:05:00 PM

Electronic Arts: Q1 Analyst Consensus Estimates

Electronic Arts (NASDAQ: EA) will be reporting its fiscal first quarter financial results after the...

Wednesday, August 4, 2021, 10:49:00 AM

Canaccord Slashes Antibe Therapeutics Price Target A Month After Drug Trial Paused

On August 3, Antibe Therapeutics Inc. (TSX: ATE) announced that they have paused their study...

Wednesday, September 29, 2021, 11:44:00 AM

Canaccord Raises Trulieve Price Target To $75 From $60

The last two weeks have been quite an enjoyable time for U.S cannabis sector investors....

Wednesday, January 13, 2021, 02:53:00 PM

Verano: Canaccord Drops Price Target After Revenue Miss

On November 16th, Verano Holdings (CSE: VRNO) announced its third quarter financial results. The company...

Thursday, November 18, 2021, 11:44:00 AM